Remus Pharmaceuticals Ltd

Remus Pharma. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Remus Pharmaceuticals Ltd

₹ 703 -1.20%
05 Jun - close price
remuspharma.com NSE - SME: REMUS
About

Incorporated in 2015, Remus Pharma Ltd is in the business of trading and export of API and Finished Formulations and in Technical consultancy services[1]

Key Points

Busienss Overview:[1][2]
RPL and its group of companies specialize in marketing pharmaceutical products with expertise in Critical Care, Neurology, Cardiology, and Diabetic categories, and recently getting off-patent molecules in various dosage forms and in complex generics. Company gets finished pharmaceutical formulations manufactured on loan license or contract manufacturing

Website NSE - SM
  • Market Cap ₹ 829 Cr.
  • Current Price ₹ 703
  • High / Low ₹ 1,022 / 580
  • Stock P/E 22.4
  • Book Value ₹ 298
  • Dividend Yield 0.14 %
  • ROCE 16.8 %
  • ROE 12.2 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is almost debt free.
  • Debtor days have improved from 107 to 59.8 days.

Cons

  • Company has a low return on equity of 13.0% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of Nifty SME Emerge

Edit Columns
Loading peers table ...

Half Yearly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2023 Mar 2024 Sep 2024 Mar 2025 Sep 2025 Mar 2026
29 185 273 348 400 453
20 165 252 323 373 424
Operating Profit 9 20 20 25 27 30
OPM % 32% 11% 8% 7% 7% 7%
2 3 3 3 3 4
Interest 0 0 1 1 1 1
Depreciation 0 1 0 1 1 1
Profit before tax 10 22 22 25 28 31
Tax % 25% 15% 16% 19% 23% 21%
6 19 19 21 22 25
EPS in Rs 4.87 13.16 11.87 13.57 14.85 16.54
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025 Mar 2026
213 620 854
184 575 797
Operating Profit 29 46 57
OPM % 14% 7% 7%
3 5 7
Interest 0 1 1
Depreciation 1 2 3
Profit before tax 30 47 59
Tax % 20% 19% 22%
24 38 46
EPS in Rs 17.69 24.64 31.39
Dividend Payout % 4% 3% 2%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 38%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 28%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: 35%
1 Year: -29%
Return on Equity
10 Years: %
5 Years: %
3 Years: 13%
Last Year: 12%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025 Mar 2026
Equity Capital 1 6 12
Reserves 156 250 339
14 23 27
161 154 201
Total Liabilities 333 433 579
14 16 18
CWIP 0 0 8
Investments 105 186 275
215 231 277
Total Assets 333 433 579

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025 Mar 2026
1 7 18
-25 -11 -15
28 6 1
Net Cash Flow 4 3 5
Free Cash Flow -11 3 4
CFO/OP 25% 32% 49%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025 Mar 2026
Debtor Days 198 64 60
Inventory Days 96 35 35
Days Payable 209 49 37
Cash Conversion Cycle 85 50 58
Working Capital Days 98 54 57
ROCE % 20% 17%

Insights

In beta
Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Number of Registered Products
Count

Log in to view insights

Please log in to see hidden values.

Login
Number of Commercialized Products
Count
Number of Countries Presence
Count
B2C Revenue Contribution
%
New Product Approvals
Count
Number of Manufacturing Partners (CMOs)
Count
Number of Ready-to-File Dossiers
Count
Total SKUs
Count

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Sep 2025Mar 2026
69.61% 70.60% 70.66% 70.84% 70.85% 70.91% 70.95%
2.38% 3.25% 3.00% 3.16% 4.77% 5.02% 5.28%
0.71% 0.67% 0.73% 0.77% 0.77% 0.77% 0.83%
27.30% 25.49% 25.61% 25.22% 23.60% 23.31% 22.93%
No. of Shareholders 8561,1241,5771,7531,8782,0322,009

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Concalls